In a 15-year follow-up of the VADT study, no differences in major cardiovascular outcomes were found among individuals with type 2 diabetes mellitus who underwent either intensive or standard glucose control. These results indicate that intensification of glycaemic control might not be expected to mitigate the risk of cardiovascular events.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).
Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).
Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).
Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
Hayward, R. A. et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372, 2197–2206 (2015).
Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).
Reaven, P. D. et al. Intensive glucose control in patients with type 2 diabetes − 15-year follow-up. N. Engl. J. Med. 380, 2215–2224 (2019).
Patel, K. V., de Albuquerque Rocha, N. & McGuire, D. K. Diabetes medications and cardiovascular outcome trials: lessons learned. Cleve. Clin. J. Med. 84, 759–767 (2017).
Das, S. R. et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol. 72, 3200–3223 (2018).
D.K.M. reports honoraria for trial leadership from AstraZeneca, Boehringer Ingelheim, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Lilly US, Merck & Co, Novo Nordisk, Pfizer and Sanofi Aventis; and honoraria for consulting for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Lilly US, Merck & Co, Metavant, Novo Nordisk, Pfizer and Sanofi Aventis. K.V.P declares no competing interests.
Rights and permissions
About this article
Cite this article
Patel, K.V., McGuire, D.K. Long-term follow-up of intensive glycaemic control in type 2 diabetes. Nat Rev Cardiol 16, 517–518 (2019). https://doi.org/10.1038/s41569-019-0241-y
This article is cited by
Implementation of Cardiometabolic Centers and Training Programs
Current Diabetes Reports (2022)
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
Current Cardiology Reports (2020)